Industry Calls for New Incentives to Spur Development of New Antibiotics

Episode Summary

Executive Summary: The episode examines the worsening antibiotic-resistance crisis and why antibiotic innovation has stalled despite clear medical need. Michael Dunn argues that scientific, clinical, and especially economic barriers—weak reimbursement, limited uptake, and high development risk—have driven big pharma away, leaving small biotechs to shoulder the burden. He and allied groups are pressing Congress for a bundle of incentives, including pull incentives and reimbursement reform, to restore a viable antibiotic pipeline.

Main Topics: Antibiotic resistance as an urgent public-health threat (Priority: 5/5): Dunn describes rising resistance in hospitals and communities, stressing that existing antibiotics are increasingly failing against dangerous pathogens and making empiric treatment harder. Why big pharma left antibiotic development (Priority: 5/5): The discussion explains how difficult discovery, high clinical-development costs, low commercial returns, and policy-driven reimbursement barriers made antibiotics unattractive for large companies. The role of small biotechs and the pipeline gap (Priority: 4/5): Small biotech firms are now carrying most antibiotic innovation, but Dunn says the number of candidates is too small to meet future demand and attrition will sharply reduce the pipeline. Congressional incentives and the GAIN Act (Priority: 5/5): Dunn reviews the GAIN Act's impact and argues that more than one incentive is needed—such as exclusivity, faster review, tax benefits, and reimbursement fixes—to make antibiotic R&D sustainable. Government funding and public-private support (Priority: 3/5): Existing support through NIAID, BARDA, and smaller discovery programs has helped early-stage work, but Dunn says it is insufficient without post-approval market incentives. Pricing politics versus societal need (Priority: 3/5): The episode closes by asking whether broader industry distrust in Congress could hinder antibiotic incentives; Dunn argues the public-health case is strong enough to justify targeted policy action.

Key Arguments: Antibiotic resistance is worsening globally and is already causing major mortality in the U.S., so new drugs are needed now, not later. Large pharmaceutical companies exited the field because antibiotic discovery is scientifically hard, development is expensive, and returns are uncertain. Hospital reimbursement systems can discourage use of newer, more expensive antibiotics, reducing uptake and undermining commercial viability. Stewardship concerns, while valid, create a second market disincentive because new antibiotics are intentionally used sparingly to preserve effectiveness. Small biotech companies are doing most of the current work, but the pipeline is too thin to replace the looming loss of effective antibiotics. The GAIN Act helped by extending exclusivity and speeding FDA review, but a broader package of incentives is required to restore investment. Congress should pair public funding with post-approval 'pull incentives' so successful antibiotic developers can earn predictable returns. Reimbursement reform, tax credits, low-interest loans, and similar measures could create a sustainable market without imposing excessive government burden.

Data Points: Estimated U.S. deaths from resistant infection last year: about 23,000 - Dunn cites this as evidence that resistance is already causing substantial harm. Time to see resistance in broadly used quinolone antibiotics: about 10 to 12 years - After this period, resistance began appearing at low levels before rising further over time. Observed quinolone resistance after later market use: about 25% of organisms - Dunn says resistance climbed significantly after roughly another decade on the market. Drug development timeline burden: hundreds of millions of dollars - He notes companies can spend this much taking drugs into clinical trials before seeing any return. Current number of antibiotics in development: about a dozen or a little over a dozen - Dunn says only a small number of candidates are in people now. Likely approvals from current pipeline: no more than 2 or 3 - He predicts most current candidates will fail due to safety, efficacy, or other issues. GAIN Act added exclusivity: 10 years of regulatory exclusivity - For eligible antibiotics, this provides market protection similar to a patent in the U.S. GAIN Act expedited FDA review: about 8 months - Dunn says this shortened the typical year-to-year-and-a-half review process.

Pivotal Quotes: "we all want the same thing, which is antibiotics to be able to treat these resistant infections" — Michael Dunn: Explaining the shared goal of industry and lawmakers within the Antimicrobial Innovation Alliance and related groups. "we probably need a kind of bundle of incentives" — Michael Dunn: Describing why the GAIN Act alone is not enough to sustain antibiotic development. "it's not acceptable this day and age to have people in jeopardy because of resistance to antibiotics" — Michael Dunn: Emphasizing the ethical urgency of restoring antibiotic innovation and access.

Implications: Without stronger incentives and reimbursement reform, antibiotic innovation will remain underfunded and fragile. For patients and hospitals, that means fewer effective options against resistant infections and greater public-health risk.